ARXS Stock Analysis: Arxis, Common Stock | NASDAQ
Aerospace & Defense | NASDAQ, USA | Market Cap: 18.445m USD | 12M Return: 12% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 47.3M
Rev. Trend: 99.6%
Warnings
Tailwinds
No distinct edge detected
Seasonality 0.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arxis, Inc. is a U.S.-based designer and manufacturer of electronic and mechanical components built for mission critical applications. The company reports through two operating segments, Electronic Components and Mechanical Components, and supplies engineered parts to other manufacturers and OEMs rather than selling finished systems directly to end users.
The Electronic Components segment produces interconnect solutions, including connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors, and resistors. The Mechanical Components segment provides precision and self-lubricating bearings, seals, springs, gaskets, ducting, and radar absorbing materials. Suppliers serving aerospace and defense platforms typically must complete extended qualification and certification processes before parts are approved for installation on aircraft, spacecraft, or military systems.
Arxis serves defense and space systems, commercial aerospace, medical technology, semiconductor testing, analytical instruments, industrial automation, and other specialized industrial sectors. The company was founded in 2019 and is headquartered in Bloomfield, Connecticut. Its Class A common stock trades on NASDAQ under the ticker ARXS, and it is classified within the Industrials sector and Aerospace & Defense industry.
- Defense spending growth boosts mission-critical component backlog
- Electronic Components segment margins expand on RF and sensor demand
- Commercial aerospace recovery drives Mechanical Components revenue
| Net Income: -49.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.48 > 1.0 |
| NWC/Revenue: 43.02% < 20% (prev 60.44%; Δ -17.42% < -1%) |
| CFO/TA 0.04 > 3% & CFO 251.2m > Net Income -49.8m |
| Net Debt (2.54b) to EBITDA (314.0m): 8.10 < 3 |
| Current Ratio: 3.70 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (404.3m) vs prev 0.00% < -2% |
| Gross Margin: 47.35% > 18% (prev 44.57%; Δ 2.78% > 0.5%) |
| Asset Turnover: 24.71% > 50% (prev 11.76%; Δ 12.95% > 0%) |
| Interest Coverage Ratio: 0.64 > 6 (EBIT TTM 113.9m / Interest Expense TTM 178.5m) |
| A: 0.10 (Total Current Assets 944.0m - Total Current Liabilities 255.2m) / Total Assets 6.64b |
| B: -0.03 (Retained Earnings -226.4m / Total Assets 6.64b) |
| C: 0.02 (EBIT TTM 113.9m / Avg Total Assets 6.48b) |
| D: 0.92 (Book Value of Equity 3.18b / Total Liabilities 3.46b) |
| Altman-Z'' = 1.65 = BB |
| DSRI: 0.75 (Receivables 323.1m/199.0m, Revenue 1.60b/743.0m) |
| GMI: 0.94 (GM 44.57% / 47.35%) |
| AQI: 0.97 (AQ_t 0.79 / AQ_t-1 0.81) |
| SGI: 2.15 (Revenue 1.60b / 743.0m) |
| TATA: -0.05 (NI -49.8m - CFO 251.2m) / TA 6.64b) |
| Beneish M = -2.48 (Cap -4..+1) = BBB |
As of July 10, 2026, the stock is trading at USD 42.54 with a total of 247,600 shares traded. Over the past week, the price has changed by -8.61%, over one month by +4.34%, over three months by +11.95% and over the past year by +11.95%.
Current recommended Stop Loss: 35.80 (which is 15.8% or 2.4 ATR below the current price).
Arxis, Common Stock has no consensus analysts rating.
P/E Trailing = 2247.5
P/E Forward = 59.8802
P/S = 11.046
P/B = 5.7961
Revenue TTM = 1.60b USD
EBIT TTM = 113.9m USD
EBITDA TTM = 314.0m USD
Long Term Debt = 2.63b USD (from longTermDebt, last quarter)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter) + Leases 64.8m
Net Debt = 2.54b USD (calculated: Debt 2.78b - CCE 238.9m)
Enterprise Value = 21.0b USD (18.4b + Debt 2.78b - CCE 238.9m)
Interest Coverage Ratio = 0.64 (Ebit TTM 113.9m / Interest Expense TTM 178.5m)
EV/FCF = 100.5x (Enterprise Value 21.0b / FCF TTM 208.8m)
FCF Yield = 0.99% (FCF TTM 208.8m / Enterprise Value 21.0b)
FCF Margin = 13.04% (FCF TTM 208.8m / Revenue TTM 1.60b)
Net Margin = -3.11% (Net Income TTM -49.8m / Revenue TTM 1.60b)
Gross Margin = 47.35% ((Revenue TTM 1.60b - Cost of Revenue TTM 843.0m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.16 (Enterprise Value 21.0b / Total Assets 6.64b)
Interest Expense / Debt = 6.42% (Interest Expense 178.5m / Debt 2.78b)
Taxrate = 22.75% (15.7m / 69.0m)
NOPAT = 88.0m (EBIT 113.9m * (1 - 22.75%))
Current Ratio = 3.70 (Total Current Assets 944.0m / Total Current Liabilities 255.2m)
Debt / Equity = 0.87 (Debt 2.78b / totalStockholderEquity, last quarter 3.18b)
Debt / EBITDA = 8.10 (Net Debt 2.54b / EBITDA 314.0m)
Debt / FCF = 12.18 (Net Debt 2.54b / FCF TTM 208.8m)
Total Stockholder Equity = 4.20b (last fiscal year from totalStockholderEquity)
RoA = -0.77% (Net Income -49.8m / Total Assets 6.64b)
RoE = -1.19% (Net Income TTM -49.8m / Total Stockholder Equity 4.20b)
RoCE = 1.67% (EBIT 113.9m / Capital Employed (Equity 4.20b + L.T.Debt 2.63b))
RoIC = 1.39% (NOPAT 88.0m / Invested Capital 6.34b)
WACC = 8.93% (E(18.4b)/V(21.2b) * Re(9.53%) + D(2.78b)/V(21.2b) * Rd(6.42%) * (1-Tc(0.23)))
Discount Rate = 9.53% (= CAPM, Blume Beta Adj.)
[DCF] Terminal Value 76.11% ; FCFF base≈142.1m ; Y1≈162.9m ; Y5≈239.7m
[DCF] Fair Price = 10.48 (EV 3.27b - Net Debt 2.54b = Equity 729.9m / Shares 69.7m; r=8.93% [WACC]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 99.59 | Revenue CAGR: 94.21% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.19 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.19 | Chg30d=-3.35% | Revisions=+0% | Analysts=6
EPS current Year (2026-12-31): EPS=0.75 | Chg30d=+0.59% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+18.2%
EPS next Year (2027-12-31): EPS=0.93 | Chg30d=+6.78% | Revisions=+0% | GrowthEPS=+23.8% | GrowthRev=+10.2%
[Analyst] Revisions Ratio: +0% (up=0, down=0)